Lane H C, Shelhamer J H, Mostowski H S, Fauci A S
J Exp Med. 1982 Jan 1;155(1):333-8. doi: 10.1084/jem.155.1.333.
A human IgMk monoclonal antibody, 2F7, of predetermined specificity, has been produced by the fusion of human peripheral blood lymphocytes with the nonsecreting mouse myeloma line SP-1. The heterohybridoma has remained stable for over 8 mo, with culture supernatants containing up to 30 micrograms/ml of specific IgM. The antibody has been shown to be capable of inducing a blastogenic response in the absence of antigen in the peripheral blood lymphocytes of normal subjects immune to the antigen. The ability to choose an antigen, immunize a human subject to that antigen, and then use the peripheral blood lymphocytes from that subject to produce antigen-specific human monoclonal antibodies should be of great value in a wide variety of investigative, diagnostic, and therapeutic endeavors.U
通过将人外周血淋巴细胞与非分泌型小鼠骨髓瘤细胞系SP-1融合,制备出了具有预定特异性的人IgMκ单克隆抗体2F7。该异源杂交瘤已稳定存在超过8个月,培养上清液中特异性IgM含量高达30微克/毫升。已证明该抗体能够在对该抗原免疫的正常受试者的外周血淋巴细胞中,在无抗原的情况下诱导增殖反应。选择一种抗原,对人类受试者进行该抗原免疫,然后使用该受试者的外周血淋巴细胞来产生抗原特异性人单克隆抗体的能力,在各种研究、诊断和治疗工作中应具有重要价值。